title: NAD degradation and regulation of CD38 expression by human monocytes/macrophages.
abstract: In recent years, evidence has accumulated that NAD+ serves as a precursor of metabolites that are involved in a number of regulatory processes. In this work we show that extracellularly added NAD+ was rapidly degraded by intact human monocytes to nicotinamide and ADP-ribose. Besides these main products, minor amounts of AMP, ADP and cADP-ribose were formed. Expression of CD38, which has been identified as NAD+-glycohydrolase (EC 3.2.2.6) degrading NAD+ into nicotinamide and ADP-ribose, was determined on freshly isolated human monocytes by flow cytometry and RT-PCR. Upon ligation with anti-CD38 mAb, CD38 underwent internalization, shedding and new expression. As monocytes possess an intracellular CD38 pool, it could serve as a source for newly expressed CD38. Differentiation of monocytes to macrophages resulted in down-regulation of surface expression of CD38. This decrease correlates with a reduction in NADase activity, indicating that the amount of functional active CD38 molecules decrease during differentiation. As CD38 mRNA was found to be diminished in macrophages, regulation of the gene product seems to occur at the level of transcription or mRNA stability.
authors.affiliation: Department of Immunobiology, Institute of Zoology, University of Leipzig, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Pfister
authors.forename: A
authors.initials: A
authors.lastname: Ogilvie
authors.forename: C P
authors.initials: CP
authors.lastname: da Silva
authors.forename: A
authors.initials: A
authors.lastname: Grahnert
authors.forename: A H
authors.initials: AH
authors.lastname: Guse
authors.forename: S
authors.initials: S
authors.lastname: Hauschildt
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D015536:Down-Regulation; D006801:Humans; D008264:Macrophages / Q000378:metabolism*; D008562:Membrane Glycoproteins; D008985:Monensin / Q000494:pharmacology; D009000:Monocytes / Q000378:metabolism*; D009243:NAD / Q000378:metabolism*; D009244:NAD+ Nucleosidase / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D009536:Niacinamide / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D008562:Membrane Glycoproteins; D011500:Protein Synthesis Inhibitors; D009243:NAD; D009536:Niacinamide; D008985:Monensin; D003513:Cycloheximide; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1